Pyxis Oncology Successfully Completes Acquisition of Apexigen
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end...
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end...
ATLANTA, GA / ACCESSWIRE / August 22, 2023 / The story of Lainie Jones, a cancer survivor from Fort Lauderdale,...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Banner Health and nference, a science-first software company transforming healthcare by making biomedical data computable, today announced a...
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancerSALT LAKE CITY,...
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22,...
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and...
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate...
Julia Macharey Photograph of Julia Macharey standing up and looking into the camera.ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS22...
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,...
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’...
London, UK – 22 August 2023 Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on...
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across PolandBERKELEY,...
Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its...
Christian Brander, Ph.D., is a leading expert on T cell responses to viral infections and brings an important blend of...
❝The commendable efforts of Dr. Lyudmila Sarder and Dr. Sarfraz Ahmad in combating the financial barriers associated with cancer treatment...
Company announces multi-year strategic partnership with AstraZeneca to accelerate early breast cancer evidence development and researchSAN FRANCISCO--(BUSINESS WIRE)--PicnicHealth, a patient-centered...
LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic...
Phase 1/2 Clinical Trial of TNX-801 for the Prevention of Mpox and Smallpox to Commence Following Submission of an IND...
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared...
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent...